Shenzhen Magicrna Biotechnology Co., Ltd

This early-stage study tests a new treatment called HN2301 in 30 people with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also see if the therapy can reduce disease activity by targeting immune cells.